• Home
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Investors
  • Aspergillosis
  • PC945
  • News
  • Contact
in vivo profile of anti-fungal PC945 has been published in Antimicrobial Agents and Chemotherapy

Pulmocide is pleased to announce another PC945 publication in Antimicrobial Agents and Chemotherapy. The publication is available to download from the link below: AAC.ASM.ORG or the PDF can be downloaded […]

03 July 2017

Read more

Pulmocide presented at Annual Conference of Microbiology society in Edinburgh, UK

Pulmocide gave an oral presentation at Annual Conference of Microbiology society 2017, held on April 02-06, 2017 in Edinburgh in UK. Title was: Preclinical characterization of PC786, a novel inhaled […]

26 April 2017

Read more

PC945 publication in Antimicrobial Agents and Chemotherapy

Pulmocide is pleased to announce a PC945 publication in Antimicrobial Agents and Chemotherapy. The Publication is available to download from the link below Download or can be found online at […]

26 April 2017

Read more

Pulmocide Raises $30 Million in Series B Financing

Funding to progress novel wholly-owned compounds for RSV and pulmonary Aspergillosis   London, UK, 20 March 2017: Pulmocide Ltd, the UK-based drug discovery company developing novel compounds designed for inhaled […]

20 March 2017

Read more

Pulmocide presented at IDweek 2016 in New Orleans, LA

Pulmocide presented two posters at the IDweek 2016, held October 26 – 30, 2016 in New Orleans, LA. These are as follows:   Anti-viral activities of PC786, a novel inhibitor […]

08 November 2016

Read more

Pulmocide presented at European Respiratory Society 2016 in London, UK

Pulmocide gave an oral presentation (as a late breaking abstract) at European respiratory society annual meeting 2016, held September 03 – 07, 2016 in London, UK. This is as follows: […]

04 October 2016

Read more

Pulmocide present at the Macrae Foundation’s XVIII International Symposium

Pulmocide presented two posters at the Macrae Foundation’s XVIII International Symposium on Respiratory Viral Infections, held March 31 – April 02, 2016 in Lisbon, Portugal. These are as follows:   […]

04 April 2016

Read more

Pulmocide present at the 7th Advances Against Aspergillosis Conference 2016

Pulmocide presented five posters at the recent 7th Advances Against Aspergillosis Conference in Manchester, and the meeting organisers published a Press Release about the work Pulmocide presented, stating: “Dr Kazuhiro Ito from Pulmocide, […]

07 March 2016

Read more

Pulmocide will present at the 7th Advances against Aspergillosis

Pulmocide will present biological profile of First-in-Class inhaled anti-fungal agent, PC945 and PC1244 on upcoming 7th Advances against Aspergillosis in Manchester UK held March 3rd – 5th. http://www.advancesagainstaspergillosis.org/2016/programme.htm

15 January 2016

Read more

  • «
  • ← Previous
  • 1
  • 2

Categories

  • Company news
  • Events
  • Presentations And Publications
  • Product news
  • Uncategorised

Company Contact

Pulmocide Ltd
44 Southampton Buildings
London
WC2A 1AP

Tel: +44 203 763 9484
Email: admin@pulmocide.com

Visit Us
  • Sitemap
  • Cookie policy
© 2021 Pulmocide
Company Reg: 06182024   265 Strand London WC2R 1BH
Web Design Agency - Brandcast Media